Your browser doesn't support javascript.
loading
Evaluation of new chlorhexidine- and cetylpyridinium chloride-based mouthrinse formulations adjunctive to scaling and root planing: pilot study.
García-Gargallo, M; Zurlohe, M; Montero, E; Alonso, B; Serrano, J; Sanz, M; Herrera, D.
Afiliação
  • García-Gargallo M; Section of Graduate Periodontology, Faculty of Odontology, University Complutense, Madrid, Spain.
  • Zurlohe M; Section of Graduate Periodontology, Faculty of Odontology, University Complutense, Madrid, Spain.
  • Montero E; Section of Graduate Periodontology, Faculty of Odontology, University Complutense, Madrid, Spain.
  • Alonso B; Etiology and Therapy of Periodontal Diseases (ETEP) Research Group, Faculty of Odontology, University Complutense, Madrid, Spain.
  • Serrano J; Etiology and Therapy of Periodontal Diseases (ETEP) Research Group, Faculty of Odontology, University Complutense, Madrid, Spain.
  • Sanz M; Etiology and Therapy of Periodontal Diseases (ETEP) Research Group, Faculty of Odontology, University Complutense, Madrid, Spain.
  • Herrera D; Etiology and Therapy of Periodontal Diseases (ETEP) Research Group, Faculty of Odontology, University Complutense, Madrid, Spain.
Int J Dent Hyg ; 15(4): 269-279, 2017 Nov.
Article em En | MEDLINE | ID: mdl-27762095
ABSTRACT

OBJECTIVE:

To compare the effect of two newly formulated chlorhexidine (CHX) and cetylpyridinium chloride (CPC) mouthrinses after scaling and root planing (SRP) in terms of clinical, microbiological, patient-based variables and adverse events, with a positive control with the same active components, already marketed and tested.

METHODS:

A pilot, randomized clinical trial, double-blind, parallel design with 1-month follow-up was conducted. Chronic periodontitis patients requiring non-surgical periodontal therapy were enrolled and randomly assigned to (i) SRP and test-1 (new reformulation 0.12% CHX and 0.05% CPC); (ii) SRP and test-2 (new formulation 0.03% CHX and 0.05% CPC); or (iii) SRP and positive control (commercial product 0.12% CHX and 0.05% CPC). All variables were evaluated at baseline and 1 month after SRP. Quantitative variables were compared by means of anova or Kruskal-Wallis test and qualitative variables by chi-square or McNemar tests.

RESULTS:

Thirty patients (10 per group) were included. After 1 month, there were significant differences among groups in plaque levels (P = 0.016) as test-1 showed less sites with plaque than test-2 (31.15% [standard error-SE 2.21%] versus 49.39% [SE 4.60%), respectively). No significant differences were found for global patient perception of the product or in adverse effects. Test groups showed better results in levels and proportions (P = 0.022) of Capnocytophaga spp.

CONCLUSIONS:

Within the limitations of this pilot study, it can be concluded that the newly formulated 0.12% CHX and 0.05% CPC mouthrinse showed larger plaque level reductions, without showing more adverse effects, when compared to the other two mouthrinses, after SRP.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cetilpiridínio / Clorexidina / Raspagem Dentária / Aplainamento Radicular / Placa Dentária / Periodontite Crônica / Anti-Infecciosos Locais / Antissépticos Bucais Tipo de estudo: Clinical_trials / Qualitative_research Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Dent Hyg Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cetilpiridínio / Clorexidina / Raspagem Dentária / Aplainamento Radicular / Placa Dentária / Periodontite Crônica / Anti-Infecciosos Locais / Antissépticos Bucais Tipo de estudo: Clinical_trials / Qualitative_research Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Dent Hyg Ano de publicação: 2017 Tipo de documento: Article